Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|November 6, 2013

ISPE Releases Report on Survey of Patient Experiences with Clinical Trial Materials

ISPE’s survey is industry’s first large-scale effort to collect data on patient experiences with clinical trial materials.

The International Society for Pharmaceutical Engineering (ISPE) released its first report on its project concerning patient experiences with clinical trial materials, ISPE announced in a press release. The survey collected data related to patients’ current and recent experiences, attitudes, and perceptions; suggestions for improvements; and demographic information. The report, released at the 2013 ISPE Annual Meeting, details the results of the survey, which measured the experiences of 1425 respondents in the industry’s first large-scale effort to collect data of this kind from patients engaged in clinical trials.

The survey found that patients are invested in compliance with study protocols when they understand what they are and the underlying rationale for the requirements. It is important to explore ways to increase patient understanding of the clinical trial process and to make compliance easier within the confines of a scientifically sound study design, commented ISPE in the release. In the survey, patients indicated a variety of ways in which “one size fits all” is not optimal from the patient perspective. The study strongly suggests that professionals will need to consider how to accommodate patients’ differing needs and preferences within the confines of a study protocol. To the extent this can be done, patient compliance may go up, concluded the ISPE Patient Survey Project Team. The survey also showed a clear need for improving the clinical trial medicine return process.

The ISPE Patient Survey Project Team will continue to review and analyze the survey data. The team currently plans to present additional findings throughout 2014 and to engage both industry leaders and regulators in a series of discussions to plan follow-up projects.

Source: ISPE


Related to this article

The Promise of Microgravity for R&D and Manufacturing
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.